ANBC INC
Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver;… Read more
ANBC INC (SYUP) - Net Assets
Latest net assets as of December 2007: $1.47 Million USD
Based on the latest financial reports, ANBC INC (SYUP) has net assets worth $1.47 Million USD as of December 2007.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.28 Million) and total liabilities ($4.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.47 Million |
| % of Total Assets | 23.38% |
| Annual Growth Rate | -1.29% |
| 5-Year Change | 7.63% |
| 10-Year Change | N/A |
| Growth Volatility | 52.42 |
ANBC INC - Net Assets Trend (2004–2017)
This chart illustrates how ANBC INC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ANBC INC (2004–2017)
The table below shows the annual net assets of ANBC INC from 2004 to 2017.
| Year | Net Assets | Change |
|---|---|---|
| 2017-12-31 | $1.86 Million | +61.17% |
| 2016-12-31 | $1.16 Million | +6320.83% |
| 2015-12-31 | $-18.58K | -101.27% |
| 2007-12-31 | $1.47 Million | -15.18% |
| 2006-12-31 | $1.73 Million | +4.80% |
| 2005-12-31 | $1.65 Million | -25.08% |
| 2004-12-31 | $2.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ANBC INC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 820130500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2017)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.30 Million | 123.40% |
| Common Stock | $124.06K | 6.66% |
| Other Comprehensive Income | $-559.97K | -30.05% |
| Other Components | $1.00 | 0.00% |
| Total Equity | $1.86 Million | 100.00% |
ANBC INC Competitors by Market Cap
The table below lists competitors of ANBC INC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MONTEGO RESOURCES INC.
F:4MO
|
$46.26 |
|
CYIOS Corporation
PINK:CYIO
|
$46.38 |
|
National Healthcare Logistics Inc
PINK:NHLG
|
$46.42 |
|
Arcandor AG
DU:ARO
|
$46.71 |
|
Itoco Inc
PINK:ITMC
|
$46.05 |
|
UPDC REAL ESTATE INVESTMENT TRUST
XNSA:UPDCREIT
|
$46.01 |
|
Man Shing Agricultural Holdings Inc
PINK:MSAH
|
$45.72 |
|
WhereverTV Broadcasting Corporation
PINK:TVTV
|
$45.46 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANBC INC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2016 to 2017, total equity changed from 1,156,016 to 1,863,193, a change of 707,177 (61.2%).
- Net income of 1,298,104 contributed positively to equity growth.
- Dividend payments of 681,298 reduced retained earnings.
- Other comprehensive income decreased equity by 590,927.
- Other factors increased equity by 681,298.
Equity Change Factors (2016 to 2017)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.30 Million | +69.67% |
| Dividends Paid | $681.30K | -36.57% |
| Other Comprehensive Income | $-590.93K | -31.72% |
| Other Changes | $681.30K | +36.57% |
| Total Change | $- | 61.17% |
Book Value vs Market Value Analysis
This analysis compares ANBC INC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.07 | $0.01 | x |
| 2016-12-31 | $0.05 | $0.01 | x |
| 2017-12-31 | $0.02 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ANBC INC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 69.67%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 41.14%
- • Asset Turnover: 1.18x
- • Equity Multiplier: 1.43x
- Recent ROE (69.67%) is above the historical average (-7.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -36.24% | -93.10% | 0.15x | 2.60x | $-1.02 Million |
| 2005 | -149.40% | -456.20% | 0.11x | 2.95x | $-2.63 Million |
| 2006 | -18.69% | -103.52% | 0.05x | 3.61x | $-496.61K |
| 2007 | -26.03% | -750.30% | 0.01x | 4.28x | $-529.08K |
| 2015 | 0.00% | 36.28% | 2.22x | 0.00x | $785.44K |
| 2016 | 104.80% | 42.25% | 1.73x | 1.43x | $1.10 Million |
| 2017 | 69.67% | 41.14% | 1.18x | 1.43x | $1.11 Million |
Industry Comparison
This section compares ANBC INC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANBC INC (SYUP) | $1.47 Million | -36.24% | 3.28x | $46.11 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |